Clinical Trials
27 trialsNCT07198074 2026-05-27
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06023862 2026-05-06
DOVE
Yonsei University
Phase 2 Recruiting
NCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06906341 2026-04-14
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
Phase 2 Recruiting
NCT03694262 2026-04-13
EndoBARR
Medical College of Wisconsin
Phase 2 Completed
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT07470853 2026-03-13
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics, Inc.
Phase 1 Recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05797168 2026-03-02
FONTANA
AstraZeneca
Phase 1/2 Recruiting
NCT07054567 2026-01-21
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT03526432 2025-10-24
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
University of Oklahoma
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT00513786 2025-03-28
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT00301964 2019-07-24
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00723255 2019-07-23
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03836157 2019-06-27
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
University of Oklahoma
Phase 2 Withdrawn
NCT00879359 2017-04-26
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00545792 2017-03-15
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01770171 2013-01-17
MITOBEVAEND2
Catholic University of the Sacred Heart
Phase 2 Unknown